Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis.

Dang J, Abulizi M, Moktefi A, El Karoui K, Deux JF, Bodez D, Le Bras F, Belhadj K, Remy P, Issaurat P, Plante-Bordeneuve V, Molinier-Frenkel V, Fanen P, Guendouz S, Kharoubi M, Itti E, Damy T, Audard V.

Mayo Clin Proc. 2019 Jun;94(6):961-975. doi: 10.1016/j.mayocp.2019.02.012. Epub 2019 May 15.

PMID:
31103217
2.

Noninvasive risk stratification of patients with transthyretin amyloidosis.

Kristen AV, Scherer K, Buss S, aus dem Siepen F, Haufe S, Bauer R, Hinderhofer K, Giannitsis E, Hardt S, Haberkorn U, Katus HA, Steen H.

JACC Cardiovasc Imaging. 2014 May;7(5):502-10. doi: 10.1016/j.jcmg.2014.03.002. Epub 2014 Apr 9.

3.

Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis.

Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, Guendouz S, Tissot CM, Hittinger L, Dubois-Randé JL, Plante-Bordeneuve V, Itti E, Meignan M, Damy T.

Amyloid. 2015;22(4):210-20. doi: 10.3109/13506129.2015.1072089. Epub 2015 Oct 14.

PMID:
26465835
4.

Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.

Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M; Immunopathology Group of the Italian Society of Nephrology.

Nephrol Dial Transplant. 2008 Mar;23(3):941-51. Epub 2007 Oct 19.

PMID:
17951308
5.

Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.

Papantoniou V, Valsamaki P, Kastritis S, Tsiouris S, Delichas Z, Papantoniou Y, Tsiouma M, Athanasoulis T, Fotopoulos A, Dimopoulos MA.

Hell J Nucl Med. 2015 Sep-Dec;18 Suppl 1:42-50.

6.

Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.

Gallego-Delgado M, González-López E, Muñoz-Beamud F, Buades J, Galán L, Muñoz-Blanco JL, Sánchez-González J, Ibáñez B, Mirelis JG, García-Pavía P.

Rev Esp Cardiol (Engl Ed). 2016 Oct;69(10):923-930. doi: 10.1016/j.rec.2016.02.027. Epub 2016 Jun 10. English, Spanish.

PMID:
27291669
7.

Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.

Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS.

JAMA Cardiol. 2016 Nov 1;1(8):880-889. doi: 10.1001/jamacardio.2016.2839.

PMID:
27557400
8.

Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.

Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, Page J, Martinez-Naharro A, Wechalekar AD, Lachmann HJ, Quarta CC, Rezk T, Mahmood S, Sachchithanantham S, Youngstein T, Whelan CJ, Lane T, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD.

Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1344-1350. doi: 10.1093/ehjci/jew325.

PMID:
28159995
9.

(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.

Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T.

Ups J Med Sci. 2016;121(1):17-24. doi: 10.3109/03009734.2015.1122687. Epub 2016 Feb 5.

10.

Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, Hazenberg BP.

Amyloid. 2014 Mar;21(1):35-44. doi: 10.3109/13506129.2013.871250. Epub 2014 Jan 23.

PMID:
24455993
11.

Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis.

Castaño A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, Bettencourt B, Gollob J, Karsten V, Vest JA, Chiuzan C, Maurer MS, Bokhari S.

J Nucl Cardiol. 2016 Dec;23(6):1355-1363. Epub 2015 Oct 9.

12.

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C.

J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84.

13.

Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.

Xin Y, Hu W, Chen X, Hu J, Sun Y, Zhao Y.

Hellenic J Cardiol. 2019 Feb 8. pii: S1109-9666(18)30543-8. doi: 10.1016/j.hjc.2019.01.015. [Epub ahead of print]

14.

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P.

Eur Heart J. 2015 Oct 7;36(38):2585-94. doi: 10.1093/eurheartj/ehv338. Epub 2015 Jul 28.

PMID:
26224076
15.

Current indications, strategies, and outcomes with cardiac transplantation for cardiac amyloidosis and sarcoidosis.

Rosenbaum AN, Edwards BS.

Curr Opin Organ Transplant. 2015 Oct;20(5):584-92. doi: 10.1097/MOT.0000000000000229. Review.

PMID:
26262459
16.

Senile systemic amyloidosis: clinical features at presentation and outcome.

Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ.

J Am Heart Assoc. 2013 Apr 22;2(2):e000098. doi: 10.1161/JAHA.113.000098.

17.

Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).

Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, Maurer MS.

Circ Heart Fail. 2011 Mar;4(2):121-8. doi: 10.1161/CIRCHEARTFAILURE.109.910455. Epub 2010 Dec 29.

18.

Magnetic Resonance in Transthyretin Cardiac Amyloidosis.

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2017 Jul 25;70(4):466-477. doi: 10.1016/j.jacc.2017.05.053.

19.

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.

Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC.

Am J Cardiol. 2018 Jan 1;121(1):107-112. doi: 10.1016/j.amjcard.2017.09.029. Epub 2017 Oct 14.

20.

Supplemental Content

Support Center